Ahmad N Fasseeh, Nada Korra, Baher Elezbawy, Amal S Sedrak, Mary Gamal, Randa Eldessouki, Mariam Eldebeiky, Mohsen George, Ahmed Seyam, Asmaa Abourawash, Ahmed Y Khalifa, Mayada Shaheen, Sherif Abaza, Zoltán Kaló
{"title":"Framework for developing cost-effectiveness analysis threshold: the case of Egypt.","authors":"Ahmad N Fasseeh, Nada Korra, Baher Elezbawy, Amal S Sedrak, Mary Gamal, Randa Eldessouki, Mariam Eldebeiky, Mohsen George, Ahmed Seyam, Asmaa Abourawash, Ahmed Y Khalifa, Mayada Shaheen, Sherif Abaza, Zoltán Kaló","doi":"10.1186/s42506-024-00159-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cost-effectiveness analyses rarely offer useful insights to policy decisions unless their results are compared against a benchmark threshold. The cost-effectiveness threshold (CET) represents the maximum acceptable monetary value for achieving a unit of health gain. This study aimed to identify CET values on a global scale, provide an overview of using multiple CETs, and propose a country-specific CET framework specifically tailored for Egypt. The proposed framework aims to consider the globally identified CETs, analyze global trends, and consider the local structure of Egypt's healthcare system.</p><p><strong>Methods: </strong>We conducted a literature review to identify CET values, with a particular focus on understanding the basis of differentiation when multiple thresholds are present. CETs of different countries were reviewed from secondary sources. Additionally, we assembled an expert panel to develop a national CET framework in Egypt and propose an initial design. This was followed by a multistakeholder workshop, bringing together representatives of different governmental bodies to vote on the threshold value and finalize the recommended framework.</p><p><strong>Results: </strong>The average CET, expressed as a percentage of the gross domestic product (GDP) per capita across all countries, was 135%, with a range of 21 to 300%. Interestingly, while the absolute value of CET increased with a country's income level, the average CET/GDP per capita showed an inverse relationship. Some countries applied multiple thresholds based on disease severity or rarity. In the case of Egypt, the consensus workshop recommended a threshold ranging from one to three times the GDP per capita, taking into account the incremental relative quality-adjusted life years (QALY) gain. For orphan medicines, a CET multiplier between 1.5 and 3.0, based on the disease rarity, was recommended. A two-times multiplier was proposed for the private reimbursement threshold compared to the public threshold.</p><p><strong>Conclusion: </strong>The CET values in most countries appear to be closely related to the GDP per capita. Higher-income countries tend to use a lower threshold as a percentage of their GDP per capita, contrasted with lower-income countries. In Egypt, experts opted for a multiple CET framework to assess the value of health technologies in terms of reimbursement and pricing.</p>","PeriodicalId":22819,"journal":{"name":"The Journal of the Egyptian Public Health Association","volume":"99 1","pages":"12"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11144683/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of the Egyptian Public Health Association","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s42506-024-00159-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Nursing","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Cost-effectiveness analyses rarely offer useful insights to policy decisions unless their results are compared against a benchmark threshold. The cost-effectiveness threshold (CET) represents the maximum acceptable monetary value for achieving a unit of health gain. This study aimed to identify CET values on a global scale, provide an overview of using multiple CETs, and propose a country-specific CET framework specifically tailored for Egypt. The proposed framework aims to consider the globally identified CETs, analyze global trends, and consider the local structure of Egypt's healthcare system.
Methods: We conducted a literature review to identify CET values, with a particular focus on understanding the basis of differentiation when multiple thresholds are present. CETs of different countries were reviewed from secondary sources. Additionally, we assembled an expert panel to develop a national CET framework in Egypt and propose an initial design. This was followed by a multistakeholder workshop, bringing together representatives of different governmental bodies to vote on the threshold value and finalize the recommended framework.
Results: The average CET, expressed as a percentage of the gross domestic product (GDP) per capita across all countries, was 135%, with a range of 21 to 300%. Interestingly, while the absolute value of CET increased with a country's income level, the average CET/GDP per capita showed an inverse relationship. Some countries applied multiple thresholds based on disease severity or rarity. In the case of Egypt, the consensus workshop recommended a threshold ranging from one to three times the GDP per capita, taking into account the incremental relative quality-adjusted life years (QALY) gain. For orphan medicines, a CET multiplier between 1.5 and 3.0, based on the disease rarity, was recommended. A two-times multiplier was proposed for the private reimbursement threshold compared to the public threshold.
Conclusion: The CET values in most countries appear to be closely related to the GDP per capita. Higher-income countries tend to use a lower threshold as a percentage of their GDP per capita, contrasted with lower-income countries. In Egypt, experts opted for a multiple CET framework to assess the value of health technologies in terms of reimbursement and pricing.
背景:除非将成本效益分析结果与基准阈值进行比较,否则成本效益分析很少能为政策决策提供有用的见解。成本效益阈值 (CET) 代表了实现单位健康收益的最大可接受货币价值。本研究旨在确定全球范围内的 CET 值,概述多种 CET 的使用情况,并提出一个专为埃及量身定制的国别 CET 框架。建议的框架旨在考虑全球范围内确定的 CET,分析全球趋势,并考虑埃及医疗保健系统的本地结构:方法:我们进行了文献综述,以确定 CET 值,尤其侧重于了解存在多个阈值时的区分依据。我们从二手资料中查阅了不同国家的 CET。此外,我们还组建了一个专家小组,以制定埃及国家 CET 框架并提出初步设计。随后,我们召开了一次多方利益相关者研讨会,汇集了不同政府机构的代表,就阈值进行投票,并最终确定了建议的框架:以人均国内生产总值 (GDP) 的百分比表示,所有国家的平均 CET 为 135%,范围在 21% 到 300% 之间。有趣的是,虽然 CET 的绝对值随着国家收入水平的提高而增加,但平均 CET/GDP 人均值却呈反比关系。一些国家根据疾病的严重程度或罕见程度采用了多种阈值。就埃及而言,考虑到相对质量调整生命年(QALY)的增量,共识研讨会建议将阈值定为人均 GDP 的 1 到 3 倍。对于孤儿药,根据疾病的罕见程度,建议采用 1.5 至 3.0 倍的 CET 乘数。结论:大多数国家的 CET 值似乎与人均国内生产总值密切相关。与低收入国家相比,高收入国家往往采用较低的阈值(占人均国内生产总值的百分比)。在埃及,专家们选择了多重 CET 框架来评估医疗技术在报销和定价方面的价值。
期刊介绍:
The journal accepts papers of original research which are not being considered for publication elsewhere and which contribute to the advancement of knowledge of Public Health at large